SCHEMBL568256

SCHEMBL568256

O=CNCc1cccc(C(F)(F)F)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADH1B P00325 1/20 0.53
ADH1C P00326 1/20 0.53
ADH1A P07327 1/20 0.53
ADH7 P40394 1/20 0.53
MLYCD O95822 1/20 0.51
TEAD1 P28347 2/20 0.50
MEN1 O00255 1/20 0.50
PLA2G1B P04054 1/20 0.50
CYP1A2 P05177 1/20 0.50
CYP3A4 P08684 1/20 0.50
GAA P10253 1/20 0.50
CYP2D6 P10635 1/20 0.50
CYP2C19 P33261 1/20 0.50
KMT2A Q03164 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
ATG4B Q9Y4P1 1/20 0.50
ACP3 P15309 1/20 0.50
TAAR1 Q96RJ0 1/20 0.50
DPP7 Q9UHL4 1/20 0.49
IDO1 P14902 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5543363 0.87 ADH1B (0.50) ADH1BADH1CADH1AADH7MLYCD
SCHEMBL4239980 0.83 DPP7 (0.59) MLYCDMEN1PLA2G1BCYP1A2CYP3A4
SCHEMBL5543041 0.83 TAAR1 (0.56) MEN1CYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL568587 0.82 RHOC (0.46) ADH1BADH1CADH1AADH7MLYCD
SCHEMBL8750958 0.81 ADH1B (0.71) ADH1BADH1CADH1AADH7LMNA
SCHEMBL5535930 0.81 TAAR1 (0.53) MLYCDMEN1CYP1A2CYP3A4CYP2D6
Hydrochloric Acid SCHEMBL3152128 0.80 RHOC (0.45) ADH1BADH1CADH1AADH7MLYCD
Hydrochloric Acid SCHEMBL3143818 0.80 RHOC (0.45) ADH1BADH1CADH1AADH7MLYCD
SCHEMBL5540234 0.80 HDAC1 (0.54) MLYCDMEN1CYP1A2CYP3A4CYP2D6
SCHEMBL541044 0.80 TAAR1 (0.58) MLYCDMEN1PLA2G1BCYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100056494-A1 PURINE COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS FOR THE TREATMENT OF PLASMODIUM RELATED DISEASES IRM LLC (BM) 2010-03-04 US claimed
EP-2124954-A2 PURINE COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS FOR THE TREATMENT OF PLASMODIUM RELATED DISEASES IRM LLC (BM) 2009-12-02 EP claimed
WO-2008094737-A2 PURINE COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS FOR THE TREATMENT OF PLASMODIUM RELATED DISEASES IRM LLC (BM) 2008-08-07 WO claimed
WO-2005016883-A2 ACRYLAMIDE DERIVATIVES AS VLA-1 INTEGRIN ANTAGONISTS AND USES THEREOF ICOS CORPORATION (US) 2005-02-24 WO claimed
US-4822903-A Fluorinated silica catalyst and preparation of aromatic/aliphatic nitriles in the presence thereof RHONE-POULENC SPECIALITES CHIMIQUES (FR) 1989-04-18 US claimed
EP-0066482-B1 METHOD FOR THE PREPARATION OF ALIPHATIC OR AROMATIC NITRILES RHONE-POULENC SPECIALITES CHIMIQUES (FR) 1984-11-28 EP claimed
EP-0066483-B1 METHOD FOR THE PREPARATION OF ALIPHATIC OR AROMATIC NITRILES RHONE-POULENC SPECIALITES CHIMIQUES (FR) 1984-11-21 EP claimed
US-4438042-A FROM AMIDES, FLUORINATE SILCEOUS CATALYSTS RHONE-POULENC SPECIALITES CHIMIQUES (FR) 1984-03-20 US claimed
US-4436669-A CYANATION, DECARBONYLATION, ACID CATALYSTS RHONE-POULENC SPECIALITES CHIMIQUES (FR) 1984-03-13 US claimed
US-9676757-B2 Heterocyclic compounds as NaV channel inhibitors and uses thereof MERCK PATENT GMBH (DE) 2017-06-13 US disclosed
CN-106459021-A Compositions and methods for treating neurodegenerative diseases 阿泽范药品公司 2017-02-22 CN disclosed
US-9540392-B2 Thienopyrimidines BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-01-10 US disclosed
US-9540392-B2 Thienopyrimidines BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-01-10 US disclosed
EP-2852596-B1 THIENOPYRIMIDINES Bayer Pharma AG (DE) 2016-06-22 EP disclosed
US-4504595-A Fluorinated silica catalyst and preparation of aromatic/aliphatic nitriles in the presence thereof RHONE-POULENC SPECIALITES CHIMIQUES (FR) 1985-03-12 US disclosed
EP-0067080-B1 N-FLUORINATED BENZYL AMIDES AND PROCESS FOR THEIR PREPARATION RHONE-POULENC SPECIALITES CHIMIQUES (FR) 1984-11-21 EP disclosed
US-4438042-A FROM AMIDES, FLUORINATE SILCEOUS CATALYSTS RHONE-POULENC SPECIALITES CHIMIQUES (FR) 1984-03-20 US disclosed
US-4436669-A CYANATION, DECARBONYLATION, ACID CATALYSTS RHONE-POULENC SPECIALITES CHIMIQUES (FR) 1984-03-13 US disclosed
EP-0067080-A1 N-fluorinated benzyl amides and process for their preparation RHONE-POULENC SPECIALITES CHIMIQUES (FR) 1982-12-15 EP disclosed
EP-0066482-A1 Method for the preparation of aliphatic or aromatic nitriles RHONE-POULENC SPECIALITES CHIMIQUES (FR) 1982-12-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100056494-A1 PURINE COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS FOR THE TREATMENT OF PLASMODIUM RELATED DISEASES ADK, PNP, DCK ADH1B 3376/4885ADH1C 4568/4885ADH1A 4682/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.